Andreia C.
- Country
- Portugal
- Department
- Unidade de Fase 1
Research Overview
- A Phase 1 Study of ZW251 in Participants with Advanced Solid Tumors
- Phase 3 Randomized Open-label Study of Opevesostat Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Data & Insights
Has run more than one trial at 21 of 125 partner sites.
Specializations
Oncology Focus
This investigator specializes in advancing treatments for metastatic castration resistant prostate cancer, conducting innovative research in urologic oncology.
- Advanced prostate cancer management
- Hormone-resistant disease therapy
- Metastatic disease treatment
The investigator evaluates novel therapeutic approaches for patients who have progressed after initial hormonal therapy.
Treatment Development
The researcher focuses on comparing emerging therapies with established androgen receptor signaling inhibitors for advanced prostate cancer.
- Novel therapeutic agents
- Comparative effectiveness research
- Treatment resistance strategies
Their work involves evaluating treatment outcomes in advanced stages of prostate cancer.
Clinical Assessment
The investigator specializes in evaluating progression-free survival and overall survival outcomes in advanced prostate cancer patients.
- Response assessment protocols
- Survival outcomes research
- Imaging-based evaluation
Their expertise includes implementing standardized criteria for assessing treatment effectiveness in clinical trials.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.